Opko Health, Inc. · NASDAQ:OPK
Opko Health — Investor Presentation (June 2014)
17 slides from Opko Health's investor presentation, Jun 17, 2014
Slide 1: Lab quality results in minutes from a finger-stick blood sample
Lab quality results in 10 minutes from a finger-stick blood sample Exhibit 99.2
Slide 2: Challenges of Obtaining Diagnostic Information
Time and discomfort for venous blood draw 1-3 day delay in lab results, diagnosis, and treatment Maintenance of certifications and lab quality COST PATIENT CARE Challenges of Obtaining Diagnostic Information
Slide 3: Real World Convenience
1-2 mins Real World Convenience mins
Slide 4: Claros Microfluidic Assay Process
Stable and contamination free reagents Analyzes results Seal Seal Seal Cassette Sample collected Cassette activated by vacuum Claros Microfluidic Assay Process
Slide 5: Sangia Microfluidic Cassette
CONVENIENT LAB QUALITY ACCURACY Sangia™ Microfluidic Cassette Single, self-contained cartridge
Slide 6: Claros 1 Update: Proven Results
ng/mL Sangia Total PSA Roche Cobas central lab system ng/mL Elecsys PSA EXCELLENT CORRELATION ensures LAB QUALITY RESULTS IN-OFFICE R of 0.970 Proven Results Claros 1 Update • Formulation of blood collector providing high reliability for results reporting • SMA Chemistry providing rapid attachment a
Slide 7: Personal risk for high-grade prostate cancer
Personal risk for high-grade prostate cancer …from a blood test
Slide 8: The Issues of PSA Screening
The Issues of PSA Screening
Slide 9: The Issues of PSA Screening
The Issues of PSA Screening OPKO Prostate Cancer is the 2"¢ leading / cause of cancer death in men 29,000+ Projected deaths in the US in 2014
Slide 10: The Issues of PSA Screening
The Issues of PSA Screening OPKO Decreased prostate cancer mortality by
Slide 11: The Issues of PSA Screening
The Issues of PSA Screening 23% Low-grade cancers BIOPSIES 54% Negative
Slide 12: The Issues of PSA Screening
The Issues of PSA Screening Biopsy side effects — Grade D Recommendation ” a
Slide 13: Poor accuracy in distinguishing cancers
Poor accuracy in distinguishing cancers Aiding Decision for Prostate Biopsy PSA SCREENING BIOPSY CANDIDATES
Slide 14: Rigorous Clinical Research
International team of researchers 3 decades of biomarker research Over 10,000 men studied 9 cohorts in peer-reviewed publications Peter Scardino (MSKCC, New York) Andrew Vickers (MSKCC, New York) Hans Lilja (MSKCC/Malmö/Oxford) Kim Pettersson (Univ. of Turku, Finland) Rigorous Clinical Research Moni
Slide 15: 7 Elements of the 4Kscore Test
Total PSA Free PSA Intact PSA hK2 Kallikrein blood tests Results of each biomarker Digital rectal exam (DRE) Prior biopsy Age of patient 7 Elements of the 4Kscore Test 46 years 53 years 65 years 68 years
Slide 16: Replication of Performance in a US Cohort
37% Negative or Gleason score 6 20% Gleason score 7 77% Negative or Gleason score 6 23% Gleason score 7 43% Biopsies avoided 9% cut off level Number of patients 1000 Current US practice Replication of Performance in a US Cohort 26 Urology Centers 1,012 Patients Prospective, Blinded Clinical study si
Slide 17: 4Kscore Test US Commercial Activities
Decrease Unnecessary Biopsies Proven Results Accurate Probability for High-grade Cancer 4Kscore Test US Commercial Activities • Post AUA follow-ups with LUGPA, PI Sites, etc. • Test seeding program with select, regional urologists • Launch web and social media platform • Complete build out of a bloo